Ceramide-regulated mitophagy and apoptosis machinery

The ceramide-regulated mitophagy and apoptosis machinery is a specialized cellular pathway that integrates sphingolipid metabolism with mitochondrial quality control and programmed cell death. This process is primarily driven by the enzyme Ceramide Synthase 1 (CERS1), which generates C18-ceramide that specifically binds to the lipidated form of Microtubule-associated protein 1 light chain 3 beta (LC3B-II) on the mitochondrial outer membrane (Sentelle et al., 2012). This direct lipid-protein interaction serves as a molecular bridge, anchoring autophagosomes to mitochondria and initiating a form of 'lethal mitophagy' that precedes and facilitates apoptosis (Ogretmen, 2018). In many cancers, such as head and neck squamous cell carcinoma, this machinery is downregulated or suppressed to avoid cell death, making its reactivation a significant therapeutic objective. Pharmacological agents like fluphenazine or mitochondria-targeted ceramide analogs (e.g., LCL-461) have been shown to stimulate this pathway to induce tumor-selective cytotoxicity (Dany et al., 2016). Beyond oncology, dysregulation of this machinery is implicated in neurodegenerative conditions where the failure to clear damaged mitochondria contributes to disease progression (Dany & Ogretmen, 2015).

Other names

Ceramide-induced mitophagyC18-ceramide-mediated mitophagyCeramide-LC3B signaling axisCERS1-dependent lethal mitophagy

Activation of Ceramide Synthase 1 (CERS1) leads to the localized production of C18-ceramide on the mitochondrial outer membrane, where it directly binds to the autophagosome-associated protein LC3B-II to recruit autophagosomes and trigger mitophagy, ultimately resulting in mitochondrial dysfunction and the induction of the intrinsic apoptotic pathway (Sentelle et al., 2012; Dany et al., 2016).